g.valckenaere
TL3 Regular · Lausanne, CH
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 4 January 2025 · last posted 3d · groups: pharmacists
124Posts here
3Topics
0Solutions
3.6kLikes received
4.8kLikes given
28Badges
421Days visited
13kPosts read
Recent activity
Full stream-
Coming back to: Time to steady state after a dose increase Replied, post #110 · Pharmacology › Pharmacokinetics · 25 Jul 2026 · 24 likes Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #61 · Analytics › HPLC & UHPLC · 23 Jul 2026 · 12 likes Post #59 and I disagree about the size of the effect, not about the direction. Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #77 · Compounds › Retatrutide · 20 Jul 2026 · 23 likes Post #73 and I disagree about the size of the effect, not about the direction. No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3…
-
Spreadsheets: an appreciation — what changed since Replied, post #106 · Lounge › Off topic · 20 Jul 2026 · 0 likes Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #60 · Compounds › Repair & healing peptides · 15 Jul 2026 · 33 likes Building on post #57 rather than restating it. BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state…
-
Pooling trials with different estimands Replied, post #93 · Evidence › Meta-analyses · 13 Jul 2026 · 15 likes Where I part company with post #91, and it is a narrow parting. Where the pooling trials with different estimands discussion usually stalls is that nobody wants to say…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #13 · Access › Insurance & coverage · 9 Jul 2026 · 0 likes Post #9 and I disagree about the size of the effect, not about the direction. What does not work: describing how the decision made you feel, however justified. The…
-
Restarting after a long gap: what the labelling implies Replied, post #14 · Practice › Dosing & titration · 6 Jul 2026 · 17 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Reused chromatograms across lots: how to spot it Replied, post #55 · Analytics › COA interpretation · 6 Jul 2026 · 0 likes Coming back to post #51, because the follow-up matters more than the original answer. Counterpoint on reused chromatograms across lots, offered without confidence: the…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #30 · Practice › Side effects · 4 Jul 2026 · 1 like Small methodological point on Muscle cramps: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #11 · Practice › Interactions · 4 Jul 2026 · 9 likes On Antibiotics, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
-
Asking a follow-up: new topic or new reply? Replied, post #30 · Start Here › How to Ask · 29 Jun 2026 · 0 likes Post #28 and I disagree about the size of the effect, not about the direction. Questions you cannot explain: "I cannot say why I am asking this, but is this compound…